General Announcement::Glenmark and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
23-Dec-2020 13:08:32
Status
New
Announcement Sub Title
Glenmark and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris
Announcement Reference
SG201223OTHRPZEO
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
23/12/2020 10:37:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris Nasal Spray across numerous markets throughout Europe

Attachments

SGX_PR_23122020.pdf
Total size =1140K